Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Sunvepra
Synonyms :
asunaprevir
Class :
Antiviral, Anti-HCV, HCV NS3/$A protease inhibitor
Brand Name :
Sunvepra
Synonyms :
asunaprevir
Class :
Antiviral, Anti-HCV, HCV NS3/$A protease inhibitor
Dosage Forms & StrengthsÂ
TabletÂ
10 mgÂ
50 mgÂ
100 mgÂ
200 mgÂ
600 mgÂ
Useful for treating long-term hepatitis C
For individuals suffering from chronic hepatitis C genotype 1 or 4 (without or with compensated cirrhosis), the recommended course of action is 100 mg twice daily via oral administration in conjunction with either daclatasvir or ribavirin, peginterferon alfa, and daclatasvir for a duration of 24 weeks.
Dosage missed: When a dose is more than eight hours away, skip it. when it is less than eight hours away, take the missed dose and go back to your regular dosing plan. It is not advised to change, discontinue, or interrupt the dose. For information on dose adjustments, see the comprehensive product guidelines for ribavirin and peginterferon alfa
Dose Adjustments
Renal dose adjustment
100 mg twice daily in hemodialysis patients
If CrCl is below 30 mL/min, then the renal dose adjustment is 100 mg daily, one time
Safety and efficacy are not seen in pediatricsÂ
Refer to the adult dosingÂ
may diminish the serum concentration when combined with tenapanor
asunaprevir: they may diminish the serum concentration of hormonal contraceptives
asunaprevir: they may diminish the serum concentration of hormonal contraceptives
asunaprevir: they may diminish the serum concentration of hormonal contraceptives
asunaprevir: they may diminish the serum concentration of hormonal contraceptives
asunaprevir: they may diminish the serum concentration of hormonal contraceptives
asunaprevir: they may diminish the serum concentration of hormonal contraceptives
drospirenone/ethinyl estradiol/levomefolateÂ
may diminish the serum concentration of Hormonal Contraceptives
etonogestrel/ethinyl estradiolÂ
may diminish the serum concentration of Hormonal Contraceptives
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
OATP1B1/1B3 (SLCO1B1/1B3) inhibitors increase the concentration of asunaprevir in the serum
OATP1B1/1B3 (SLCO1B1/1B3) inhibitors increase the concentration of asunaprevir in the serum
OATP1B1/1B3 (SLCO1B1/1B3) inhibitors increase the concentration of asunaprevir in the serum
OATP1B1/1B3 (SLCO1B1/1B3) inhibitors increase the concentration of asunaprevir in the serum
OATP1B1/1B3 (SLCO1B1/1B3) inhibitors increase the concentration of asunaprevir in the serum
may enhance the concentration of serum when combined with asunaprevir
may enhance the concentration of serum when combined with asunaprevir
may enhance the concentration of serum when combined with asunaprevir
may enhance the concentration of serum when combined with asunaprevir
may enhance the concentration of serum when combined with asunaprevir
asunaprevir: they may enhance the serum concentration of CYP3A Inhibitors
asunaprevir: they may enhance the serum concentration of CYP3A Inhibitors
asunaprevir: they may enhance the serum concentration of CYP3A Inhibitors
asunaprevir: they may enhance the serum concentration of CYP3A Inhibitors
asunaprevir: they may enhance the serum concentration of CYP3A Inhibitors
CYP3A strong enhancers of the small intestine may reduce the bioavailability of asunaprevir
when both drugs are combined, there may be an increase in the serum concentration of asunaprevir
OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors increase the concentration of asunaprevir in serum
may enhance the serum concentration
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of OATP1/1B3 substrates
may enhance the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors
may enhance the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors
may decrease the serum concentration of CYP3A4 Inducers
it may enhance the metabolism when combined with oxcarbazepine
Combining asunaprevir with pranlukast may cause a reduction in the asunaprevir’s metabolism
When domeperidone and asunaprevir is used together, this leads to reduction in the domeperidone’s metabolism
When asunaprevir is used together with fluconazole, this leads to reduction in the asunaprevir metabolism
When asunaprevir is used together with elbasvir, this leads to a rise in the concentration serum of elbasvir
When asunaprevir is used together with grazoprevir, this leads to a rise in the concentration serum of grazoprevir
When asunaprevir is used together with ouabain, this leads to reduction in asunaprevir excretion
asunaprevir will decrease serum concentration of midazolam
asunaprevir will increase serum concentration of dabigatran
when coupled with asunaprevir, abemaciclib's serum levels can rise
combining asunaprevir with abametapir can raise its serum concentration
when coupled with asunaprevir, abiraterone can lower asunaprevir's metabolism
when coupled with asunaprevir, abrocitinib's metabolism may be slowed down
when coupled with asunaprevir, acalabrutinib's metabolism can be accelerated
acebutolol and asunaprevir together can lower acebutolol's metabolism
combining with asunaprevir can lead to a decreased metabolism of zimelidine
the metabolism of asunaprevir can be reduced when combined with ziprasidone
when combined with asunaprevir, the metabolism of zolpidem may decrease
combining with asunaprevir can result in a decreased metabolism of zonisamide
the metabolism of asunaprevir can be diminished when combined with zopiclone
when combined with asunaprevir, the metabolism of zuclopenthixol may be decreased
the serum concentration of zuranolone may be reduced when combined with asunaprevir
When indisulam is used together with asunaprevir, this leads to a reduction in asunaprevir metabolism
when combined with indalpine, the metabolism of asunaprevir may decrease.
asunaprevir: it may decrease the therapeutic efficacy of etynodiol
asunaprevir: it may decrease the metabolism of dextropropoxyphene
the serum concentration of digitoxin can be increased when it is combined with asunaprevir
asunaprevir's absorption may be reduced by almasilate, resulting in lower serum concentrations and potentially decreased efficacy
may enhance HMG-CoA Reductase Inhibitors' serum levels
may increase the myopathic effect of HMG-CoA Reductase Inhibitors
combining asunaprevir may result in a decreased excretion of cholecystokinin
the serum levels of asunaprevir may be increased
the rate of metabolism of asunaprevir may be reduced
When asunaprevir is used together with oliceridine, this leads to enhanced concentration serum of oliceridine
When asunaprevir is used together with lomitapide, this leads to an enhancement in lomitapide’s metabolism
could lead to a reduction in the concentration serum of Hormonal Contraceptives
could lead to a reduction in the concentration serum of Hormonal Contraceptives
could lead to a reduction in the concentration serum of Hormonal Contraceptives
could lead to a reduction in the concentration serum of Hormonal Contraceptives
could lead to a reduction in the concentration serum of Hormonal Contraceptives
could lead to a reduction in the concentration serum of Hormonal Contraceptives
bazedoxifene/conjugated estrogens
could lead to a reduction in the concentration serum of Hormonal Contraceptives
could lead to a reduction in the concentration serum of Hormonal Contraceptives
could lead to a reduction in the concentration serum of Hormonal Contraceptives
it decreases the concentration of hormonal contraceptives in serum
Actions and Spectrum:Â
Actions:Â
Asunaprevir functions as a protease inhibitor, selectively focusing on and preventing the hepatitis C virus protease enzyme from being active. This action helps treat hepatitis C infections by stopping the virus from multiplying and spreading.Â
Spectrum:Â
Asunaprevir demonstrates its broad spectrum of efficacy against particular targets or activities, with a focus on impeding the hepatitis C virus’s activity.Â
Frequency not definedÂ
Black Box Warning:Â
Not recommended for moderate or severe cases (Child-Pugh classes B or C)Â
Contraindication/Caution:Â
ContraindicationsÂ
CautionsÂ
Pregnancy consideration:Â Â
No data is available regarding the administration of the drug during pregnancy.Â
Breastfeeding warnings:Â Â
No data is available regarding the excretion of drug in breast milk.Â
Pregnancy category:Â
Category A: well-controlled and satisfactory studies show no risk to the fetus in the first or later trimester.Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: No data is available for the drug under this category.Â
Pharmacology:Â
Asunaprevir is a serine protease inhibitor that inhibits the NS3/4A (nonstructural protein) of the hepatitis C virus (HCV). It inhibits the activity of viral replication by binding to the NS3/4A protease active site. Â
Pharmacodynamics:Â
In vitro studies have demonstrated significant antiviral activity against HCV replicon cell systems, with EC50 values of 4nm and 1nm for HCV genotypes 1a and 1b, respectively. However, its activity against genotypes 2 and 3 is limited, making asunaprevir a highly selective anti-HCV agent effective only against HCV genotypes 1a and 1b.
Clinical studies have revealed that asunaprevir leads to substantial reductions in HCV RNA levels in patients with genotype one infection, with a mean maximum reduction from baseline of approximately 2.87 log10 IU/ml.Â
In monotherapy clinical studies, asunaprevir demonstrated a mean maximum decline in HCV RNA ranging from 0.28 to 2.87 log10 IU/ml across increasing doses from 10 to 600 mg. As part of combination therapy, a sustained virological response was achieved in 83-92% of patients. These findings highlight the well-tolerated nature of asunaprevir in clinical settings. Â
Pharmacokinetics:Â
AbsorptionÂ
The bioavailability is 9.3%Â
The time to achieve peak effect is 1-4 hoursÂ
DistributionÂ
Protein-bound is >99%Â
The volume of distribution is 194 L.Â
MetabolismÂ
Undergoes unaltered drug and metabolite oxidative processing in the liver, primarily carried out by the CYP3A4 enzyme.Â
Elimination and ExcretionÂ
The half-life is 17-23 hoursÂ
The drug is excreted 84% in feces and less than 1% in urine.Â
Administration:Â
Asunaprevir is generally given orally, and the recommended dosage and administration instructions may differ depending on the patient’s condition and the guidance of the prescribing healthcare provider. Adhering to the prescribed dosage and administration schedule provided by the healthcare professional is crucial. Typically, the medication is taken with food.
Without first speaking with their doctor, they should not stop taking the drug or alter the dosage. If there are any uncertainties or questions about the administration of asunaprevir, it is recommended that you seek clarification from a qualified healthcare professional.Â
Patient information leafletÂ
Generic Name: asunaprevirÂ
Pronounced: ah-SOO-nah-PREV-irÂ
Why do we use asunaprevir?Â
Asunaprevir is employed as a primary antiviral medication for managing chronic hepatitis C virus (HCV) infection. Categorized as a protease inhibitor, asunaprevir operates by impeding the activity of the NS3/4A protease enzyme crucial for the replication of the hepatitis C virus. Through this inhibition, asunaprevir effectively hinders virus replication, leading to a reduction in its presence within the body.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
